EyeGate Pharmaceuticals Inc. (EYEG)
EyeGate Pharmaceuticals Statistics
Share Statistics
EyeGate Pharmaceuticals has 760.93K shares outstanding. The number of shares has increased by null% in one year.
Shares Outstanding | 760.93K |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Institutions (%) | 8.45% |
Shares Floating | - |
Failed to Deliver (FTD) Shares | 263 |
FTD / Avg. Volume | 24.47% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
Short Interest | 0 |
Short % of Shares Out | 0% |
Short % of Float | 0% |
Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is 17.54 and the forward PE ratio is null. EyeGate Pharmaceuticals's PEG ratio is 0.
PE Ratio | 17.54 |
Forward PE | n/a |
PS Ratio | 8.46 |
Forward PS | 48 |
PB Ratio | 5.26 |
P/FCF Ratio | 15.84 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for EyeGate Pharmaceuticals Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.94, with a Debt / Equity ratio of 0.
Current Ratio | 4.94 |
Quick Ratio | 4.94 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0.22 |
Cash Flow / Debt | 149.71 |
Interest Coverage | -122.89 |
Financial Efficiency
Return on equity (ROE) is 0.3% and return on capital (ROIC) is 13.93%.
Return on Equity (ROE) | 0.3% |
Return on Assets (ROA) | 0.21% |
Return on Capital (ROIC) | 13.93% |
Revenue Per Employee | $1,144,285.71 |
Profits Per Employee | $551,767.36 |
Employee Count | 14 |
Asset Turnover | 0.44 |
Inventory Turnover | n/a |
Taxes
Income Tax | -2.07M |
Effective Tax Rate | -0.36 |
Stock Price Statistics
The stock price has increased by -1.26% in the last 52 weeks. The beta is 0.35, so EyeGate Pharmaceuticals's price volatility has been higher than the market average.
Beta | 0.35 |
52-Week Price Change | -1.26% |
50-Day Moving Average | 35.36 |
200-Day Moving Average | 35.86 |
Relative Strength Index (RSI) | 51.81 |
Average Volume (20 Days) | 1.07K |
Income Statement
In the last 12 months, EyeGate Pharmaceuticals had revenue of 16.02M and earned 7.72M in profits. Earnings per share was 1.99.
Revenue | 16.02M |
Gross Profit | 16.02M |
Operating Income | 2.64M |
Net Income | 7.72M |
EBITDA | 0 |
EBIT | 2.64M |
Earnings Per Share (EPS) | 1.99 |
Balance Sheet
The company has 3.79M in cash and 57.17K in debt, giving a net cash position of 3.74M.
Cash & Cash Equivalents | 3.79M |
Total Debt | 57.17K |
Net Cash | 3.74M |
Retained Earnings | -143.38M |
Total Assets | 38.51M |
Working Capital | 28.12M |
Cash Flow
In the last 12 months, operating cash flow was 8.56M and capital expenditures -6.26K, giving a free cash flow of 8.55M.
Operating Cash Flow | 8.56M |
Capital Expenditures | -6.26K |
Free Cash Flow | 8.55M |
FCF Per Share | 2.21 |
Margins
Gross margin is 100%, with operating and profit margins of 16.45% and 48.22%.
Gross Margin | 100% |
Operating Margin | 16.45% |
Pretax Margin | 35.33% |
Profit Margin | 48.22% |
EBITDA Margin | n/a |
EBIT Margin | 16.45% |
FCF Margin | 53.39% |
Dividends & Yields
EYEG pays an annual dividend of $2.26, which amounts to a dividend yield of 5.89%.
Dividend Per Share | $2.26 |
Dividend Yield | 5.89% |
Dividend Growth (YoY) | -4.54% |
Payout Ratio | -127.66% |
Earnings Yield | 5.64% |
FCF Yield | 31.84% |
Analyst Forecast
Currently there are no analyst rating for EYEG.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 30, 2019. It was a backward split with a ratio of 1:15.
Last Split Date | Aug 30, 2019 |
Split Type | backward |
Split Ratio | 1:15 |
Scores
Altman Z-Score | -3.28 |
Piotroski F-Score | 4 |